About ISSX vi
Abstracts of Plenary and Symposia Presentations (Sunday, May 10, 2009)
Plenary Session 1: Drug Transporters in the New Drug Discovery and Development
Abstract: 1 1
Symposium 1: Transporters as Useful Targets for Drug Discovery and Development
Abstracts: 2–5 1–3
Symposium 3: Novel Strategies for the Discovery and Development of Safer Drugs
Abstracts: 6–9 3–6
Symposium 4: The Exposure, Metabolism, and Health Effects of Arsenic
Abstracts: 10–13 6–8
Abstracts of Plenary and Symposia Presentations (Monday, May 11, 2009)
Plenary Session 2: UDP-Glucuronosyltransferase and Drug Glucuronidation-linking Structure, Function, and Kinetics
Abstract: 14 8
Symposium 5: Drug-Metabolizing Enzymes for Activation and Detoxification of Xenobiotics
Abstracts: 15–18 8–10
Symposium 6: Dietary Modulation of Xenobiotics Transport and Metabolism
Abstracts: 19–22 10–12
Symposium 7: Transcriptional Regulation of Drug Metabolism
Abstracts: 23–25 12–13
Symposium 8: Oxidative Stress and Inflammation: Mechanisms and Treatments
Abstracts: 26–29 14–15
Plenary and Symposia Presentations (Tuesday, May 12, 2009)
Plenary Session 3: Discovery of Biomarkers for Gene Expression and Drug Toxicity and Efficacy
Abstracts: 30 15–16
Symposium 9: Promise of Pharmacogenomics in the Era of Personalized Drug Therapy
Abstracts: 31–33 16–17
Symposium 10: Herbal Medicine Development: Bedside to Bench Top
Abstracts: 34–37 17–19
Finalists for the Predoctoral (Graduate) Poster Awards Competition (Sunday, May 10–Tuesday, May 12, 2009)
Abstracts: 49–53 19–22
Finalists for the Postdoctoral Poster Awards Competition (Monday, May 18–Wednesday, May 20, 2009)
Abstracts: 54–56, 58 22–23
Abstracts of Poster Presentations (Monday, May 19, 2009)
Analytical
Abstracts: 59–62, 136–143 23–25, 58–62
Conjugation Reactions and Enzymes
Abstracts: 63, 149–154 25–26, 64–67
Cytochrome P450
Abstracts: 64–69 26–28
Differences in Metabolism (i.e., species, gender, age, and diseases)
Abstracts: 70–71 29–30
Disposition
Abstracts: 72–74 30–31
Drug Discovery and Development
Abstracts: 75–78 31–33
Drug Interaction
Abstracts: 79–80 33–34
Enzyme Induction
Abstracts: 81–82 34–35
Enzyme Inhibition/Inactivation
Abstracts: 83–85 35–36
Gene Expression and Regulation
Abstracts: 86–100 36–41
Genomics/Metabonomics/Proteomics
Abstracts: 101 41–42
Hepatocytes
Abstracts: 102 42
High-Throughput Techniques
Abstracts: 103–104 42–43
In Vitro Techniques
Abstracts: 105 43
Mechanisms of Xenobiotic Toxicities
Abstracts: 106–112 44–47
Metabolic Profiling
Abstracts: 113–116 47–49
Metabolism
Abstracts: 117–119 49–50
Non-P450 Phase I Enzymes
Abstracts: 120–121 51
Pharmacogenetics
Abstracts: 122–126 52–54
Pharmacokinetics and Pharmacodynamics
Abstracts: 127–131 54–56
Transporters
Abstracts: 132–135 56–58
Bioavailability
Abstracts: 144–147 62–64
Clearance Prediction
Abstract: 148 64
Abstracts of Poster Presentations (Monday, May 11, 2009)
Cytochrome P450
Abstracts: 155–163 67–71
Disposition
Abstracts: 164–165 71–72
Drug Discovery and Development
Abstracts: 166–190 72–82
Drug Interaction
Abstracts: 191–195 83–84
Enzyme Induction
Abstract: 196 84
Enzyme Inhibition/Inactivation
Abstracts: 197–198 84–85
Gene Expression and Regulation
Abstracts: 199–201 85–86
Hepatocytes
Abstract: 202 87
In Silico
Abstract: 203 87
In Vitro Techniques
Abstracts: 204–205 87–88
Mechanisms of Xenobiotic Toxicities
Abstracts: 206–219 88–94
Metabolic Profiling
Abstracts: 220–222 94–95
Metabolism
Abstracts: 223–227 95–98
Non-P450 Phase I Enzymes
Abstract: 228 98
Pharmacogenetics
Abstracts: 229–236 98–102
Pharmacokinetics and Pharmacodynamics
Abstracts: 237–244 102–105
Transporters
Abstracts: 245–260 105–112
Author Index 113
Terms Index 119